Shattuck Labs, Inc. (STTK)

USD 0.91

(-29.97%)

Market Cap (In USD)

43.6 Million

Revenue (In USD)

1.65 Million

Net Income (In USD)

-87.29 Million

Avg. Volume

202.75 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.94-11.76
PE
-0.61
EPS
-1.49
Beta Value
1.863
ISIN
US82024L1035
CUSIP
82024L103
CIK
1680367
Shares
47899200.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Taylor H. Schreiber M.D., Ph.D.
Employee Count
-
Website
https://www.shattucklabs.com
Ipo Date
2020-10-09
Details
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.